comparemela.com

Latest Breaking News On - Clinical stage - Page 5 : comparemela.com

Harvard Apparatus Regenerative Technology Schedules

ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)

Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced Last Patient Last Vi

Passage Bio to Present at Guggenheim s 5th Annual Inflammation, Neurology & Immunology Conference

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be available on

Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ETDOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET. The program will feature Dr. Fiona Simpkins, Perelman School of Medicin

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.